CyclopharmASX:CYC 46 Days Payable is 144.54 as of Dec. 2025, which is 20% below its 10-year median of 179.62. GuruFocus rates ASX:CYC with a GF Score™ of 46/100 and a GF Value™ of A$0.84 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 115 Medical Distribution companies, Cyclopharm ranks better than 81.74% on this metric.
Cyclopharm's average Accounts Payable for the
six
months ended in Dec. 2025 was A$5.79 Mil. Cyclopharm's Cost of Goods Sold for the
six
months ended in Dec. 2025 was A$7.31 Mil.
Hence, Cyclopharm's Days Payable for the
six
months ended in Dec. 2025 was 144.54.
The historical rank and industry rank for Cyclopharm's Days Payable or its related term are showing as below:
ASX:CYC'
s Days Payable Range Over the Past 10 Years
Min: 99.13 Med: 179.62 Max: 241.77
Current: 129.23
During the past 13 years, Cyclopharm's highest Days Payable was 241.77. The lowest was 99.13. And the median was 179.62.
ASX:CYC's Days Payable is ranked better than 81.74% of 115
companies
in the Medical Distribution industry
Industry Median: 79.81
vs ASX:CYC: 129.23
Cyclopharm's Days Payable
declined
from Dec. 2024 (252.60) to Dec. 2025 (144.54).
It may suggest that Cyclopharmaccelerated paying its suppliers.
Cyclopharm Days Payable Related Terms
Cyclopharm Days Payable Historical Data
* Premium members only.
The historical data trend for Cyclopharm's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Cyclopharm's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyclopharm Days Payable vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cyclopharm's Days Payable distribution charts can be found below:
* The bar in red indicates where Cyclopharm's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cyclopharm's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclopharm (ASX:CYC) has a Days Payable of 144.54 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cyclopharm and its competitors. This is 20% below median its historical median of 179.62. Over the past decade, Cyclopharm's Days Payable has ranged from 99.13 to 241.77. According to the industry distribution chart, Cyclopharm ranks #21 out of 115 companies in the Medical Distribution industry, placing it in the top 18.3%.
Is Cyclopharm's Days Payable too high?
Cyclopharm's current Days Payable of 144.54 is 20% below median its 10-year median of 179.62. Over the past 10 years, this metric has ranged from a low of 99.13 to a high of 241.77. The Medical Distribution industry median Days Payable is 79.81. Cyclopharm's value of 144.54 is 81.1% above this industry median. Based on the distribution chart, Cyclopharm ranks #21 out of 115 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Cyclopharm has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's Days Payable compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Cyclopharm ranks #21 out of 115 companies for Days Payable. This places Cyclopharm in the top 18% of its industry — outperforming the majority of peers. The industry median Days Payable is 79.81. Cyclopharm's value of 144.54 is 81.1% above this benchmark. Historically, Cyclopharm's own Days Payable has ranged from 99.13 to 241.77 over the past decade. While the company's 10-year median is 179.62 vs. the industry median of 79.81, Cyclopharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Distribution company?
The median Days Payable among Medical Distribution companies is 79.81, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cyclopharm's current Days Payable of 144.54 is 81.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cyclopharm and its competitors. For the Medical Distribution industry, the median Days Payable is 79.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyclopharm's current Days Payable is 144.54, which is 20% below median its own 10-year median of 179.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.84, compared to a current price of A$0.50 — trading 40.5% below its estimated fair value. The current Days Payable is 144.54, which is 20% below median its 10-year median of 179.62 and 81.1% above the Medical Distribution industry median of 79.81. Cyclopharm's overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current Days Payable is 144.54 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyclopharm (ASX:CYC) Overvalued in 2026?
Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued.
The current stock price of A$0.50 is trading 40.5% below its estimated GF Value™ of A$0.84.
GuruFocus considers Cyclopharm to be Possible Value Trap.
Key valuation signals for ASX:CYC:
Days Payable: 144.54 (20% below median its 10-year median of 179.62)
GF Value™: A$0.84 vs. price of A$0.50 (40.5% below fair value)
Industry Position: 81.1% above the Medical Distribution median (#21 of 115)
No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
46GF Score
Get the complete analysis for ASX:CYC
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CYC has been successfully added to your 
